

**Acknowledgment and Consent for Disclosure of
Section 712(c)(2)(B) of the Federal Food, Drug, and Cosmetic Act
and 18 U.S.C. §208(b)(3)
Particular Matter Waivers**

Name: Robert Califf, M.D.

Committee: Endocrinologic & Metabolic Drugs Advisory Committee

Meeting Date(s): July 1-2, 2008

I acknowledge that contingent upon public disclosure of the following financial interests submitted on my FDA Form 3410 and related to the agenda item: to discuss the role of cardiovascular assessment in the pre-approval and post-approval settings for drugs and biologics developed for the treatment of type 2 diabetes mellitus, I am eligible to receive a particular matter waivers under Section 712(c)(2)(B) and 18 U.S.C. §208(b)(3).

Type of Interest	Involvement	Magnitude
Employer's Research Contract/Grant	2 Affected Firms	Greater than \$300,000 per year
Employer's Research Contract/Grant	1 Affected Firm	Under negotiation for magnitude
Consulting	1 Affected Firm	Less than \$10,000 per year
Consulting	1 Affected Firm	Between \$10,001 to \$50,000 per year

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued by reading the statement into the record at the time of the meeting. I understand that without public disclosure of these interests, the waivers are not valid.

_____/S/_____
Signature

_____/6/12/08_____
Date